Cystatin C - a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients

Strahlenther Onkol. 2011 Mar;187(3):191-201. doi: 10.1007/s00066-010-2203-5. Epub 2011 Feb 24.

Abstract

Purpose: Determination of renal function is a prerequisite for planning therapy in cancer patients. Limitations of creatinine as marker for the glomerular filtration rate (GFR) led to the proposal of cystatin C as a more accurate biomarker especially in mild renal insufficiency or in patients with low muscle mass. We compared the accuracy of cystatin C- and creatinine-based equations to estimate GFR in head and neck cancer (HNC) patients receiving platinum-based radiochemotherapy.

Patients and methods: The study population consisted of 52 HNC patients (GFR range, 37-105 mL/min/1.73 m(2) complemented by 17 patients with known renal insufficiency (GFR range, 10-60 mL/min/1.73 m(2)). Intraclass correlation coefficients were calculated between the reference method (51)Cr-EDTA clearance and estimated GFR by creatinine clearance and equations based on creatinine (Cockroft-Gault, modification of diet in renal disease (MDRD), Wright) or cystatin C (Larsson, Dade-Behring, Hoek). In addition, sensitivity and specificity to discriminate GFR > 60 mL/min/1.73 m(2) were evaluated by receiver operating characteristic curve (ROC).

Results: The highest correlation coefficients were found for the cystatin C-based estimates in comparison with creatinine-based estimates or creatinine clearance, even though Bland-Altman plots revealed GFR overestimation for all equations tested. The cystatin C-based Hoek formula exhibited the highest overall precision and accuracy. GFR of < 60 mL/min/1.73 m(2) was assumed as a cut-off for chemotherapy. ROC analyses revealed the highest AUC to predict a GFR > 60 mL/min/1.73 m(2) for the creatinine-based Wright formula, closely followed by the MDRD formula and cystatin C-based equations of Larsson, Dade-Behring, and Hoek.

Conclusion: Cystatin C-based GFR estimates showed the overall strongest correlation to the reference method. Thus, we recommend cystatin C for GFR estimation in HNC patients as an alternative method to the estimated creatinine clearance in clinical practice.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma / physiopathology*
  • Adenocarcinoma / radiotherapy*
  • Adult
  • Aged
  • Carcinoma, Mucoepidermoid / drug therapy
  • Carcinoma, Mucoepidermoid / physiopathology*
  • Carcinoma, Mucoepidermoid / radiotherapy*
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / physiopathology*
  • Carcinoma, Squamous Cell / radiotherapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Creatinine / blood
  • Cystatin C / blood*
  • Female
  • Glomerular Filtration Rate / physiology*
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Otorhinolaryngologic Neoplasms / drug therapy
  • Otorhinolaryngologic Neoplasms / pathology
  • Otorhinolaryngologic Neoplasms / physiopathology*
  • Otorhinolaryngologic Neoplasms / radiotherapy*
  • Predictive Value of Tests
  • Reference Values
  • Renal Insufficiency / physiopathology

Substances

  • Cystatin C
  • Creatinine